YY/T 1849-2022 in English
VALIDRecombinant collagen protein
- Issued on:2022-01-13
- Implemented on:2022-08-01
- File Format:PDF
- Delivery:Via email within 1~3 business days
$243.00
本文件规定了重组胶原蛋白的质量控制要求、检测指标及其检测方法等。本文件适用于作为医疗器械原材料的重组胶原蛋白的质量控制。
Introduction
Technical background and evolution of standards
As the first pharmaceutical industry standard specifically for recombinant collagen, YY/T 1849-2022 fills the standard gap in the application of genetically engineered collagen products in medical devices. This standard integrates the requirements of the general introduction to human recombinant DNA protein products in the Pharmacopoeia of the People's Republic of China and the product series standards for tissue engineering medical devices, reflecting the following technological evolution:
- Shift from traditional tissue extraction of collagen to preparation using genetic recombination technology
- Establishment of a multidimensional analytical method for triple helix structure confirmation
- Introduction of mass spectrometry technology for characteristic peptide quantification
Core quality control system
| Control dimensions | Natural collagen | Recombinant collagen | Key differences |
|---|---|---|---|
| Structure confirmation | Triple helix structure verification | Additional verification of gene sequence matching required | Recombinant products may lack natural conformation |
| Impurity Control | Animal Virus Risk | Host Protein/DNA Residues | Expression System Determines Differences in Impurity Spectrum |
| Biological Function | Abundant Empirical Data | Need to Establish a New Evaluation System | The Function of Recombinant Products May Change |
Key Implementation Points for Key Testing Items
5.7 Structural Characterization Case
For the verification of triple helix structure, the standard recommends the use of a combined analysis of Circular Dichroism (CD), Differential Scanning Calorimetry (DSC) and Protease Sensitivity Test:
- The CD spectrum should have a characteristic positive peak at 221nm
- DSC detection depolymerization temperature must be consistent with the reference product
- The difference in trypsin digestion rate should be ≤15%
Implementation recommendations and risk control
Based on the standard requirements, manufacturers should pay special attention to:
- Expression system selection: Escherichia coli expression needs to focus on endotoxin control, and eukaryotic systems need to verify glycosylation modification
- Reference product establishment: It is recommended to freeze ≥3 batches of representative stock solutions as physical and chemical references
- Immunogenicity assessment: New recombinant sequences must undergo immunotoxicology studies as required by GB/T 16886.20

Loading PDF document...
Error loading PDF. Please make sure the file is valid and try again.
We also recommend
-

YY 0059-1991 in English
dental handpiece
1991-11-21 -

YY/T 0085.1-1992 in English
Pulse vacuum pressure steam sterilizer
1992-01-21 -

YY/T 0085.2-1992 in English
Forevacuum pressure steam sterilizer
1992-01-21 -

YY/T 0063-1991 in English
Medical diagnostic X-ray tube assembly focus characteristics
1991-11-21 -

YY 0188-1993 in English
hip prosthesis
1993-07-19 -

YY/T 0106-1993 in English
Medical Diagnostic X-ray machine general technical conditions
1993-02-10 -

YY 0141-1993 in English
Test methods for suspended particles in clean rooms and clean areas of the pharmaceutical industry
1993-10-18 -

YY 0068.4-2009/XG1-2023 in English
Medical electrical equipment―Part 1:General requirements for basic safety and essential performance, includes Amendment 1
2009-12-30